drugset / Trial / NCT05493709
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Phase 3
Completed
94 enrolled
Foresee Pharmaceuticals Co., Ltd.
Changchun GeneScience Pharmaceutical Co., Ltd. · collabQPS Holdings LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
Timeline
- Start
- 2023-06-02
- Primary completion
- 2025-12-07
- Completion
- 2026-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 42 mg | Subcutaneous |